The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s COVID-19 vaccine, following six reported cases of rare but severe types of blood clots following the vaccine’s administration.

Nearly 7 million doses of the Johnson & Johnson vaccine have been administered in the U.S. since it was authorized for emergency use in March, meaning that the adverse events represent less than one in a million of those vaccinated. The six reported cases involve women between the ages of 18 and 48, with symptoms occurring 6 to 13 days after vaccination. 

FDA and CDC, while stressing that this pause is only a recommendation, said the time will be used to prepare health care professionals to diagnose, treat and report similar cases. To discuss the situation, CDC has ordered an April 14 emergency meeting of its independent Advisory Committee on Immunization Practices to provide advice on what should be said to clinicians and the public.

The AHA is monitoring this situation and will provide updates as new information becomes available.
 

Related News Articles

Headline
In this AHA video for Mother’s Day, part of AHA’s #MyWhy social media campaign, a pregnant health care worker explains why she chose to get…
Headline
Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose…
Headline
The American Medical Association yesterday announced Current Procedural Terminology codes for reporting the two-dose Novavax COVID-19 vaccine and its…
Headline
The Health Resources and Services Administration will provide nearly $1 billion to small rural hospitals, critical access hospitals and rural health clinics to…
Headline
Pfizer Inc. today said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19…
Headline
The AHA today urged the Centers for Medicare & Medicaid Services to apply its recently increased Medicare payment rates for COVID-19 vaccine…